Health & Wellness Industry Roundup: Week Of July 18

  
Generate a summary of this article
Listen to this article
Beta

Ortek plots bacteriotherapy path; Puerto Rico proposal under congressional scrutiny; UK pans Special K claim; firms sponsor Olympians; and more news in brief.

A licensing partner for oral care and microbiome technology firm Ortek Therapeutics Inc. receives a patent from the US Patent and Trademark Office for topical application of a zinc- and arginine-based composition to prevent or treat drug-resistant bacteria and suppress body odor. Ortek, of Roslyn Heights, N.Y., has exclusive international licensing rights to this patent awarded to the Research Foundation of State University of New York, Albany, and developed at Stony Brook University. Ortek, which is seeking licensing partners to develop and commercialize applications, says a practical use of the technology is in bacteriotherapy, a strategy to combat potential pathogens while creating favorable ecological conditions in the microbiome to allow beneficial bacteria to proliferate. The technology is intended for topical administration in forms including soaps, sprays, drops, aerosols, powders, roll-ons, lotions, patches and ointments in OTC and Rx products.

A congressional task force headed by dietary supplement industry champion Sen. Orrin Hatch, R-UT, will investigate the impact of Puerto...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from United States

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Lauder’s Outgoing CFO Breaks Down Global Prestige Beauty, Firm’s Transition Moment

 
• By Eileen Francis

Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 
• By Malcolm Spicer

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

More from North America

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process. 

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 
• By Malcolm Spicer

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 
• By Malcolm Spicer

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.